Moderna, Inc. (MRNA)
After hours:
| Previous close | 176.35 |
| Open | 172.74 |
| Bid | 173.05 x 1100 |
| Ask | 173.64 x 1400 |
| Day's range | 172.40 - 178.74 |
| 52-week range | 115.03 - 217.25 |
| Volume | |
| Avg. volume | 5,022,640 |
| Market cap | 66.559B |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | 6.48 |
| EPS (TTM) | 26.74 |
| Earnings date | 23 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 226.64 |
- Motley Fool
3 No-Brainer Growth Stocks to Buy in 2023
In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.
- Business Wire
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn
- Motley Fool
Is Moderna Stock a Buy Now?
The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders. Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year. At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world.
